Half-year report · HY
3583.TEDINET S100WZXL
Period2025-04-01 → 2025-09-30
Filed2025-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥3.1bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥6.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥352m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥489m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥351m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥814m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥454m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥353m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥452m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥355m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥580m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥302m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥355m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥302m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥10.0bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥9.8bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥9.6bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥3.0bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥3.1bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥7.0bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥6.7bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥6.5bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.7bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.9bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.7bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.8bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.5bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.8bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥277m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥637m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥313m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥47m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥160m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥202m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥248m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥562m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥391m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥129.18 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥209.05 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥108.1 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 69.8% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.1% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.6% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Medical Productsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥829m |
| Medical Productsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥827m |
| Medical Productsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥1m |
| Medical Productsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥58m |
| Technological Productsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥2.2bn |
| Technological Productsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥2.2bn |
| Technological Productsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥448m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥3.1bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥3.1bn |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥1m |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥507m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥3.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥3.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥1m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥507m |
| Medical Productsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥817m |
| Medical Productsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥817m |
| Medical Productsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥513,000 |
| Medical Productsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥65m |
| Technological Productsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥2.2bn |
| Technological Productsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.2bn |
| Technological Productsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥598m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥3.0bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥3.0bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥513,000 |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥663m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥3.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥3.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥513,000 |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥663m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 531
| Item | Context | Value | Unit |
|---|---|---|---|
| Proceeds from long term loans payable fin cf | Prior1InterimDuration | 100000000 | JPY |
| Proceeds from long term loans payable fin cf | InterimDuration | 200000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1InterimDuration | -422532000 | JPY |
| Repayment of long term loans payable fin cf | InterimDuration | -291190000 | JPY |
| Cash dividends paid fin cf | Prior1InterimDuration | -61245000 | JPY |
| Cash dividends paid fin cf | InterimDuration | -100629000 | JPY |
| Repayments of lease obligations fin cf | Prior1InterimDuration | -7397000 | JPY |
| Repayments of lease obligations fin cf | InterimDuration | -7836000 | JPY |
| Proceeds from sales of treasury stock fin cf | Prior1InterimDuration | － | JPY |
| Proceeds from sales of treasury stock fin cf | InterimDuration | 54000 | JPY |
| Purchase of treasury stock fin cf | Prior1InterimDuration | -262000 | JPY |
| Purchase of treasury stock fin cf | InterimDuration | -48195000 | JPY |
| Net cash provided by used in financing activities | Prior1InterimDuration | -391438000 | JPY |
| Net cash provided by used in financing activities | InterimDuration | -247796000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1InterimDuration | -11418000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | InterimDuration | 9558000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration | -292502000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration | -8200000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 2840544000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 2750379000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 2548041000 | JPY |
| Cash and cash equivalents | InterimInstant | 2742179000 | JPY |
| Shipment expenses sga | Prior1InterimDuration | 52448000 | JPY |
| Shipment expenses sga | InterimDuration | 66611000 | JPY |
| Payrolls allowances and bonuses sga | Prior1InterimDuration | 257651000 | JPY |
| Payrolls allowances and bonuses sga | InterimDuration | 267041000 | JPY |
| Provision for bonuses sga | Prior1InterimDuration | 50200000 | JPY |
| Provision for bonuses sga | InterimDuration | 33444000 | JPY |
| Retirement benefit expenses sga | Prior1InterimDuration | 10179000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 10689000 | JPY |
| Provision for jesop expense sga | Prior1InterimDuration | 10232000 | JPY |
| Provision for jesop expense sga | InterimDuration | 14036000 | JPY |
| Welfare expenses sga | Prior1InterimDuration | 41216000 | JPY |
| Welfare expenses sga | InterimDuration | 41690000 | JPY |
| Research and development expenses sga | Prior1InterimDuration | 71192000 | JPY |
| Research and development expenses sga | InterimDuration | 59941000 | JPY |
| Rent expenses sga | Prior1InterimDuration | 17991000 | JPY |
| Rent expenses sga | InterimDuration | 17880000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E00584-000TechnologicalProductsReportableSegmentsMember | 2174483000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E00584-000MedicalProductsReportableSegmentsMember | 816808000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReportableSegmentsMember | 2991292000 | JPY |
| Revenues from external customers | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 2991292000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E00584-000TechnologicalProductsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E00584-000MedicalProductsReportableSegmentsMember | 513000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReportableSegmentsMember | 513000 | JPY |
| Transactions with other segments | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 513000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E00584-000TechnologicalProductsReportableSegmentsMember | 2174483000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E00584-000MedicalProductsReportableSegmentsMember | 817321000 | JPY |
| Net sales | Prior1InterimDuration_ReportableSegmentsMember | 2991805000 | JPY |
| Net sales | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 2991805000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |